Barclays PLC Aeglea Bio Therapeutics, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
SELL
$0.5 - $2.66 $3,280 - $17,452
-6,561 Reduced 98.51%
99 $0
Q1 2022

May 16, 2022
SELL
$1.87 - $4.77 $79,461 - $202,691
-42,493 Reduced 86.45%
6,660 $16,000
Q4 2021

Feb 14, 2022
BUY
$3.5 - $8.42 $114,201 - $274,736
32,629 Added 197.46%
49,153 $233,000
Q3 2021

Nov 09, 2021
BUY
$6.03 - $7.95 $65,461 - $86,305
10,856 Added 191.53%
16,524 $131,000
Q2 2021

Aug 13, 2021
SELL
$6.32 - $8.38 $204,098 - $270,623
-32,294 Reduced 85.07%
5,668 $40,000
Q1 2021

May 13, 2021
BUY
$6.76 - $8.57 $157,115 - $199,183
23,242 Added 157.89%
37,962 $301,000
Q4 2020

Feb 11, 2021
SELL
$7.02 - $9.83 $34,510 - $48,324
-4,916 Reduced 25.04%
14,720 $116,000
Q3 2020

Nov 12, 2020
SELL
$6.51 - $9.33 $22,791 - $32,664
-3,501 Reduced 15.13%
19,636 $139,000
Q2 2020

Aug 12, 2020
BUY
$4.01 - $11.04 $57,992 - $159,660
14,462 Added 166.71%
23,137 $213,000
Q1 2020

May 13, 2020
SELL
$3.51 - $8.48 $62,499 - $150,994
-17,806 Reduced 67.24%
8,675 $41,000
Q4 2019

Feb 10, 2020
BUY
$7.23 - $8.55 $92,934 - $109,901
12,854 Added 94.33%
26,481 $202,000
Q3 2019

Nov 14, 2019
SELL
$6.42 - $9.0 $22,925 - $32,139
-3,571 Reduced 20.76%
13,627 $105,000
Q2 2019

Aug 14, 2019
BUY
$6.1 - $8.78 $28,828 - $41,494
4,726 Added 37.89%
17,198 $118,000
Q1 2019

May 15, 2019
BUY
$7.6 - $9.4 $94,787 - $117,236
12,472 New
12,472 $100,000
Q4 2018

Feb 14, 2019
SELL
$6.51 - $10.19 $39,795 - $62,291
-6,113 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$8.24 - $11.0 $40,516 - $54,087
4,917 Added 411.12%
6,113 $59,000
Q2 2018

Aug 14, 2018
SELL
$7.87 - $10.89 $15,771 - $21,823
-2,004 Reduced 62.63%
1,196 $13,000
Q1 2018

May 15, 2018
BUY
$5.07 - $10.9 $16,224 - $34,880
3,200 New
3,200 $32,000

Others Institutions Holding AGLE

# of Institutions
1
Shares Held
241K
Call Options Held
0
Put Options Held
0
View Full List

About Aeglea BioTherapeutics, Inc.

AGLE Quotes by TradingView
  • Ticker AGLE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,172,500
  • Market Cap $1.69B
  • Description
  • Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...
More about AGLE
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email